Human platelet antigens (HPA) are polymorphisms in platelet antigens. These can stimulate production of alloantibodies (that is, antibodies against other people's antigens) in recipients of transfused platelets from donors with different HPAs.

2023年6月27日 · 其发病机制与人类血小板抗原（HPA）-1a产生特异性同种抗体有关。 大多数患者可检测出IgG型抗HPA-1a抗体，一般持续存在12～15个月。

Fetal neonatal alloimmune thrombocytopenia (FNAIT) is caused by maternal alloantibodies directed against the human platelet antigens (mostly HPA‐1a or HPA‐5b) of the (unborn) child and can lead to severe bleeding. Anti‐HPA‐1a‐mediated FNAIT shows a severe clinical outcome more often than anti‐HPA‐5b‐mediated FNAIT.

This is a molecular test to genotype the HPA-1 DNA sequence. The wild-type platelet glycoprotein HPA-1a (PL A1) is present in approximately 98% of the general population. A single nucleotide polymorphism changes the antigenic determinant from HLA-1a (PL A1) to HPA-1b (PL A2).

2023年7月6日 · Human platelet antigen-1a (HPA-1a) negative platelets are used to treat neonatal alloimmune thrombocytopenia (NAIT), a bleeding disorder in newborns.

2017年4月21日 · We found that human anti-HPA-1a mAb 26.4 partially inhibits adhesion and migratory capacity of HTR8/SVneo cells. Our findings suggest that anti-HPA-1a antibodies may affect trophoblast functions crucial for normal placental development.

2017年4月21日 · Results: We found that human anti-HPA-1a mAb 26.4 partially inhibits adhesion and migratory capacity of HTR8/SVneo cells. Conclusions: Our findings suggest that anti-HPA-1a antibodies may affect trophoblast functions crucial for normal placental development.

研究表明，血小板抗体是影响血小板输注效果的主要免疫因素之一。 目前发现与PTR相关的HPA主要是HPA-1b、5a和5b [7]。 若患者输注与其本身HPA不相合的血小板，就可能产生HPA抗体，引起病理性同种免疫反应，导致血小板破坏。

2021年3月18日 · 结果 针对HPA-1a、HPA-3a、HPA-5b 3种抗体的MAIPA定量检测方法得到了优化,检测范围分别为0~4 IU、0~20 AU、0~20 AU,准确性（回收率）分别为96.20%~103.10%、97.90%~103.10%、100.20%~106.10%。 批内精密度 [变异系数（CV）]分别为1.3%~3.6%、2.7%~5.2%和4.7%~5.3%,批间精密度（CV）分别为4.0%~5.6%、4.4%~5.9%和3.2%~6.3%,检测人源抗体抗A、抗B、抗I、抗P均无明显阳性,具有良好的特异性。

2024年2月24日 · An incompatibility between human platelet antigen (HPA)-1a accounts for the majority of FNAIT cases. Binding of HPA-1a-specific alloantibodies to their target on fetal platelets and endothelial cells can induce apoptosis of megakaryocytes, disrupt platelet function, and impair angiogenesis.